Literature DB >> 30764649

Trajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study.

Tyler S Kaster1, Jonathan Downar1, Fidel Vila-Rodriguez1, Kevin E Thorpe1, Kfir Feffer1, Yoshihiro Noda1, Peter Giacobbe1, Yuliya Knyahnytska1, Sidney H Kennedy1, Raymond W Lam1, Zafiris J Daskalakis1, Daniel M Blumberger1.   

Abstract

OBJECTIVE: Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for refractory major depressive disorder, yet no studies have characterized trajectories of rTMS response. The aim of this study was to characterize response trajectories for patients with major depression undergoing left dorsolateral prefrontal cortex rTMS and to determine associated baseline clinical characteristics.
METHODS: This was a secondary analysis of a randomized noninferiority trial (N=388) comparing conventional 10-Hz rTMS and intermittent theta burst stimulation (iTBS) rTMS. Participants were adult outpatients who had a primary diagnosis of major depressive disorder, had a score ≥18 on the 17-item Hamilton Depression Rating Scale (HAM-D), and did not respond to one to three adequate antidepressant trials. Treatment was either conventional 10-Hz rTMS or iTBS rTMS applied to the dorsolateral prefrontal cortex, 5 days/week over 4-6 weeks (20-30 sessions). Group-based trajectory modeling was applied to identify HAM-D response trajectories, and regression techniques were used to identify associated characteristics.
RESULTS: Four trajectories were identified: nonresponse (N=43, 11%); rapid response (N=73, 19%); higher baseline symptoms, linear response (N=118, 30%); and lower baseline symptoms, linear response (N=154, 40%). Significant differences in response and remission rates between trajectories were detectable by week 1. There was no association between treatment protocol and response trajectory. Higher baseline scores on the HAM-D and the Quick Inventory of Depression Symptomatology-Self-Report (QIDS-SR) were associated with the nonresponse trajectory, and older age, lower QIDS-SR score, and lack of benzodiazepine use were associated with the rapid response trajectory.
CONCLUSIONS: Major depression shows distinct response trajectories to rTMS, which are associated with baseline clinical characteristics but not treatment protocol. These response trajectories with differential response to rTMS raise the possibility of developing individualized treatment protocols.

Entities:  

Keywords:  Depressive Disorder, Treatment-Resistant; Longitudinal Studies, Clinical Trials; Mood Disorders-Unipolar; Transcranial Magnetic Stimulation; Treatment Outcome

Mesh:

Year:  2019        PMID: 30764649     DOI: 10.1176/appi.ajp.2018.18091096

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

1.  Dorsolateral prefrontal γ-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy

Authors:  Jennifer G. Levitt; Guldamla Kalender; Joseph O’Neill; Joel P. Diaz; Ian A. Cook; Nathaniel Ginder; David Krantz; Michael J. Minzenberg; Nikita Vince-Cruz; Lydia D. Nguyen; Jeffry R. Alger; Andrew F. Leuchter
Journal:  J Psychiatry Neurosci       Date:  2019-11-01       Impact factor: 6.186

2.  Identification of Clinical Features and Biomarkers that may inform a Personalized Approach to rTMS for Depression.

Authors:  Sarah L Garnaat; Andrew M Fukuda; Shiwen Yuan; Linda L Carpenter
Journal:  Pers Med Psychiatry       Date:  2019-10-18

Review 3.  Psychiatric Applications of Repetitive Transcranial Magnetic Stimulation.

Authors:  Katharine G Marder; Tracy Barbour; Stephen Ferber; Olanike Idowu; Amanda Itzkoff
Journal:  Focus (Am Psychiatr Publ)       Date:  2022-01-25

4.  Distinct trajectories of response to prefrontal tDCS in major depression: results from a 3-arm randomized controlled trial.

Authors:  Stephan A Goerigk; Frank Padberg; Markus Bühner; Nina Sarubin; Tyler S Kaster; Zafiris J Daskalakis; Daniel M Blumberger; Lucas Borrione; Lais B Razza; Andre R Brunoni
Journal:  Neuropsychopharmacology       Date:  2020-12-21       Impact factor: 7.853

5.  Accelerated brain aging predicts impulsivity and symptom severity in depression.

Authors:  Katharine Dunlop; Lindsay W Victoria; Jonathan Downar; Faith M Gunning; Conor Liston
Journal:  Neuropsychopharmacology       Date:  2021-01-25       Impact factor: 7.853

6.  Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-05-06

Review 7.  Use of Repetitive Transcranial Magnetic Stimulation in the Treatment of Neuropsychiatric and Neurocognitive Symptoms Associated With Concussion in Military Populations.

Authors:  Lindsay M Oberman; Shannon Exley; Noah S Philip; Shan H Siddiqi; Maheen M Adamson; David L Brody
Journal:  J Head Trauma Rehabil       Date:  2020 Nov/Dec       Impact factor: 3.117

8.  Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions.

Authors:  Chris Baeken; Anna-Katharine Brem; Martijn Arns; Andre R Brunoni; Igor Filipčić; Ana Ganho-Ávila; Berthold Langguth; Frank Padberg; Emmanuel Poulet; Fady Rachid; Alexander T Sack; Marie-Anne Vanderhasselt; Djamila Bennabi
Journal:  Curr Opin Psychiatry       Date:  2019-09       Impact factor: 4.741

9.  Predictors of remission after repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: An analysis from the randomised non-inferiority THREE-D trial.

Authors:  Alisson P Trevizol; Jonathan Downar; Fidel Vila-Rodriguez; Kevin E Thorpe; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  EClinicalMedicine       Date:  2020-04-30

10.  Concomitant lorazepam use and antidepressive efficacy of repetitive transcranial magnetic stimulation in a naturalistic setting.

Authors:  M Deppe; M Abdelnaim; T Hebel; P M Kreuzer; T B Poeppl; B Langguth; M Schecklmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-07-09       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.